Rachel McMinn
CIK 1606302 · Chief Executive Officer · last filed 2026-03-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$39.12M
Companies
2
Total Filings
24
Lifetime Open-Market Net
$354.3K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NGNE | Chief Executive Officer | 1,344,307 | $29.10 | $39.12M | $895.0K | 5 | 2026-03-30 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Chief Strategy Officer | 16,875 | $19.00 | $320.6K | -$540.7K | 19 | 2017-10-04 |
Recent Filings · Page 3 of 3
24 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-11-04 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Sell (S) | −125 | -$20.0K | EDGAR |
| 2015-10-05 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Grant (A) | +4,050 | $0 | EDGAR |
| 2015-08-04 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Sell (S) | −127 | -$33.3K | EDGAR |
| 2015-07-17 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Sell (S) | −503 | -$128.3K | EDGAR |
Showing 21–24 of 24
Prev
Page 3 of 3
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.